Irisin level in type 2 diabetic patients and its relation to glycemic control and diabetic complications
- 5 Downloads
Irisin is a new myokin and adipokine related to human obesity and insulin resistance status.
To investigate whether serum irisin is related to glycemic indicators and micro and macrvascular complications in patients with T2DM.
The study included 60 T2DM patients and 30 healthy controls. Anthropometric measures, neurological assessment, and fundus examination were done to all patients. Correlations of serum irisin and blood glucose, glycosylated hemoglobin (HbA1C), urinary albumin, estimated glomerular filtration rat (eGFR), C-reactive protein (CRP), and carotid intima media thickness (CIMT) were analyzed using Spearman’s correlation coefficient.
In diabetic patients, there was negative correlation between irisin level and duration of diabetes(r = − 0.302, p = 0.023), body mass index (BMI) (r = − 0.663, p < 0.001), HbA1C (r = − 0.528, p < 0.001), urinary albumin (r = − 0.439, p < 0.001), CRP (r = − 0.692, p < 0.001), and CIMT (r = − 0.807, p < 0.001). Levels of irisin were significantly lower in patients with peripheral diabetic neuropathy (PDN) compared to those without PDN (0.11 ± 0.05 vs. 0.22 ± 0.11 ng/ml, p < 0.001). Levels of irisin were not significantly different between patients with diabetic retinopathy and those with normal fundi.
In T2DM patients, negative correlations between irisin and HbA1C, urinary albumin, and CIMT were found. Moreover, patients with diabetic neuropathy had lower irisin levels.
KeywordsType 2 diabetes Irisin Carotid intima media thickness Nephropathy Neuropathy
All authors acknowledge their gratitude to the staff members of inpatient and clinics of internal medicine department for their help and support.
Compliance with ethical standards
This cross-sectional study was conducted from April 2014 till April 2015 after approval of the institutional ethical committee. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.
Informed consent was obtained from all patients for being included in the study.
- 4.Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61:1725–38.CrossRefGoogle Scholar
- 11.Zhang M, Chen P, Chen S, Sun Q, Zeng QC, Chen JY, et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci. 2014;18:1567–72.Google Scholar
- 12.American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2014;37:887.Google Scholar
- 35.Van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediat Inflamm. 2010;2010:15.Google Scholar